After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Pacira BioSciences Inc is $1.13B. A total of 0.76 million shares were traded on the day, compared to an average of 673.39K shares.
In the most recent transaction, BIGAL MARCELO sold 4,912 shares of PCRX for 23.67 per share on Aug 07 ’25. After the transaction, the Director now owns 11,393 company shares. In a previous transaction on Aug 07 ’25, BIGAL MARCELO bought 4,912 shares at 23.67 per share.
Among the insiders who sold shares, RIKER LAUREN disposed of 5,578 shares on Jun 04 ’25 at a per-share price of $26.21. This resulted in the Senior Vice President, Finance holding 59,564 shares of PCRX after the transaction. In another insider transaction, WILLIAMS KRISTEN sold 14,376 shares at $26.24 per share on Jun 04 ’25. Company shares held by the Chief Administrative Officer now total 161,574.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, PCRX has a high of $27.64 and a low of $11.16.
As of this writing, PCRX has an earnings estimate of $0.64 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of $0.68 per share and a lower estimate of $0.62. The company reported an EPS of $0.79 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $16.88, while its Total Shareholder’s Equity was $730.41M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Buy with a score of 3.50.
